Praxis Precision Medicines (PRAX) EBIAT (2022 - 2025)
Praxis Precision Medicines (PRAX) has 4 years of EBIAT data on record, last reported at -$88.9 million in Q4 2025.
- For Q4 2025, EBIAT fell 51.52% year-over-year to -$88.9 million; the TTM value through Dec 2025 reached -$303.3 million, down 65.9%, while the annual FY2025 figure was -$303.3 million, 65.88% down from the prior year.
- EBIAT reached -$88.9 million in Q4 2025 per PRAX's latest filing, down from -$74.0 million in the prior quarter.
- Across five years, EBIAT topped out at -$24.6 million in Q3 2023 and bottomed at -$88.9 million in Q4 2025.
- Average EBIAT over 4 years is -$51.5 million, with a median of -$47.9 million recorded in 2022.
- Peak YoY movement for EBIAT: soared 45.49% in 2023, then plummeted 118.32% in 2024.
- A 4-year view of EBIAT shows it stood at -$41.2 million in 2022, then skyrocketed by 34.72% to -$26.9 million in 2023, then tumbled by 118.32% to -$58.7 million in 2024, then tumbled by 51.52% to -$88.9 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were -$88.9 million in Q4 2025, -$74.0 million in Q3 2025, and -$71.1 million in Q2 2025.